Sorafenib inhibits tumor cell proliferation, increases the rate of apoptosis, and inhibits tumor angiogenesis by inhibiting the serine–threonine kinases CRAF and BRAF and the receptor tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptor β (PDGFR-β) [39, 40]. The gene discussed is RAF1; the disease is neoplasm.